Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02077465 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 1 study of Chronic Obstructive Pulmonary Disease, sponsored by Gilead Sciences.

Completed
Registry status
Phase 1
Development phase
11
Enrollment target
5
Study locations

NCT02077465 is a Phase 1 study of Chronic Obstructive Pulmonary Disease that has completed, run by Gilead Sciences. The registered enrollment target is 11 participants, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02077465, a Phase 1 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 1
Development phase
11 participants
Enrollment target
5
Study locations

Study Summary

The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.

Interventions

  • DRUG Andecaliximab
  • DRUG Placebo to match Andecaliximab

Study Locations (5)

Florida

  • Advanced Pharma CR, LLC - Miami
  • Elite Research Institute - Miami
  • Compass Research, LLC - Orlando

New York

  • University at Buffalo CTRC - Buffalo

Tennessee

  • Volunteer Research Group - Knoxville

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2014-03-11
Est. Completion 2014-10-27
Phase Phase 1

Sponsor

Gilead Sciences

504 total trials

What the Registry Record Tells You About NCT02077465

The ClinicalTrials.gov registry entry for NCT02077465 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (99% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Andecaliximab is the first listed.

NCT02077465 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Florida, New York, Tennessee.

Frequently Asked Questions

What is clinical trial NCT02077465 about?

NCT02077465 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)". The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.

What is the current status of trial NCT02077465?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2014-03-11. Estimated completion is 2014-10-27.

What conditions does trial NCT02077465 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.

What interventions are being tested in trial NCT02077465?

The interventions under investigation include: Andecaliximab (DRUG), Placebo to match Andecaliximab (DRUG).

Who is sponsoring clinical trial NCT02077465?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02077465 being conducted?

This trial has 5 study locations across Florida, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Obstructive Pulmonary Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.